why choose us

First received: May 24, 2023

Clinical Trial: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Prostatic Neoplasms, Castration-Resistant

Study Type: INTERVENTIONAL


Official Title: Phase I Dose Escalation Study to Evaluate Tolerability and Safety of 225Ac-PSMA I&T in Patients With Metastatic Prostate Cancer

Brief Summary: 225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer.PSMA is overexpressed on prostate cancer cells.Actium-225 is an alpha emitting radionuclide.When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.

Read more